229 related articles for article (PubMed ID: 21152443)
21. Determination of permeability and lipophilicity of pyrazolo-pyrimidine tyrosine kinase inhibitors and correlation with biological data.
Dreassi E; Zizzari AT; Falchi F; Schenone S; Santucci A; Maga G; Botta M
Eur J Med Chem; 2009 Sep; 44(9):3712-7. PubMed ID: 19410338
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
23. Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase.
Fraser C; Dawson JC; Dowling R; Houston DR; Weiss JT; Munro AF; Muir M; Harrington L; Webster SP; Frame MC; Brunton VG; Patton EE; Carragher NO; Unciti-Broceta A
J Med Chem; 2016 May; 59(10):4697-710. PubMed ID: 27115835
[TBL] [Abstract][Full Text] [Related]
24. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells.
Yuan CX; Zhou ZW; Yang YX; He ZX; Zhang X; Wang D; Yang T; Pan SY; Chen XW; Zhou SF
Drug Des Devel Ther; 2015; 9():1293-318. PubMed ID: 25767376
[TBL] [Abstract][Full Text] [Related]
25. A Conformation Selective Mode of Inhibiting SRC Improves Drug Efficacy and Tolerability.
Temps C; Lietha D; Webb ER; Li XF; Dawson JC; Muir M; Macleod KG; Valero T; Munro AF; Contreras-Montoya R; Luque-Ortega JR; Fraser C; Beetham H; Schoenherr C; Lopalco M; Arends MJ; Frame MC; Qian BZ; Brunton VG; Carragher NO; Unciti-Broceta A
Cancer Res; 2021 Nov; 81(21):5438-5450. PubMed ID: 34417202
[TBL] [Abstract][Full Text] [Related]
26. Characterization of compound 584, an Abl kinase inhibitor with lasting effects.
Puttini M; Redaelli S; Moretti L; Brussolo S; Gunby RH; Mologni L; Marchesi E; Cleris L; Donella-Deana A; Drueckes P; Sala E; Lucchini V; Kubbutat M; Formelli F; Zambon A; Scapozza L; Gambacorti-Passerini C
Haematologica; 2008 May; 93(5):653-61. PubMed ID: 18367480
[TBL] [Abstract][Full Text] [Related]
27. The effect of the dual Src/Abl kinase inhibitor AZD0530 on Philadelphia positive leukaemia cell lines.
Gwanmesia PM; Romanski A; Schwarz K; Bacic B; Ruthardt M; Ottmann OG
BMC Cancer; 2009 Feb; 9():53. PubMed ID: 19216789
[TBL] [Abstract][Full Text] [Related]
28. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
29. ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines.
Chevalier C; Cannet A; Descamps S; Sirvent A; Simon V; Roche S; Benistant C
PLoS One; 2015; 10(3):e0118854. PubMed ID: 25803821
[TBL] [Abstract][Full Text] [Related]
30. Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts.
Lee YC; Huang CF; Murshed M; Chu K; Araujo JC; Ye X; deCrombrugghe B; Yu-Lee LY; Gallick GE; Lin SH
Oncogene; 2010 Jun; 29(22):3196-207. PubMed ID: 20228840
[TBL] [Abstract][Full Text] [Related]
31. Novel pyrazolo[3,4-d]pyrimidines: design, synthesis, anticancer activity, dual EGFR/ErbB2 receptor tyrosine kinases inhibitory activity, effects on cell cycle profile and caspase-3-mediated apoptosis.
Maher M; Kassab AE; Zaher AF; Mahmoud Z
J Enzyme Inhib Med Chem; 2019 Dec; 34(1):532-546. PubMed ID: 30688116
[TBL] [Abstract][Full Text] [Related]
32. Abl family kinases regulate FcγR-mediated phagocytosis in murine macrophages.
Greuber EK; Pendergast AM
J Immunol; 2012 Dec; 189(11):5382-92. PubMed ID: 23100514
[TBL] [Abstract][Full Text] [Related]
33. Synthesis, anticancer evaluation, and molecular docking studies of some novel 4,6-disubstituted pyrazolo[3,4-d]pyrimidines as cyclin-dependent kinase 2 (CDK2) inhibitors.
Cherukupalli S; Chandrasekaran B; Kryštof V; Aleti RR; Sayyad N; Merugu SR; Kushwaha ND; Karpoormath R
Bioorg Chem; 2018 Sep; 79():46-59. PubMed ID: 29753773
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Finn RS; Dering J; Ginther C; Wilson CA; Glaspy P; Tchekmedyian N; Slamon DJ
Breast Cancer Res Treat; 2007 Nov; 105(3):319-26. PubMed ID: 17268817
[TBL] [Abstract][Full Text] [Related]
35. Effects of multi and selective targeted tyrosine kinase inhibitors on function and signaling of different bladder cancer cells.
Hänze J; Kessel F; Di Fazio P; Hofmann R; Hegele A
Biomed Pharmacother; 2018 Oct; 106():316-325. PubMed ID: 29966976
[TBL] [Abstract][Full Text] [Related]
36. Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis in colon cancer cell lines.
Golubovskaya VM; Gross S; Kaur AS; Wilson RI; Xu LH; Yang XH; Cance WG
Mol Cancer Res; 2003 Aug; 1(10):755-64. PubMed ID: 12939401
[TBL] [Abstract][Full Text] [Related]
37. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
38. Dasatinib (BMS-354825) tyrosine kinase inhibitor suppresses invasion and induces cell cycle arrest and apoptosis of head and neck squamous cell carcinoma and non-small cell lung cancer cells.
Johnson FM; Saigal B; Talpaz M; Donato NJ
Clin Cancer Res; 2005 Oct; 11(19 Pt 1):6924-32. PubMed ID: 16203784
[TBL] [Abstract][Full Text] [Related]
39. A novel inhibitor of the tyrosine kinase Src suppresses phosphorylation of its major cellular substrates and reduces bone resorption in vitro and in rodent models in vivo.
Missbach M; Jeschke M; Feyen J; Müller K; Glatt M; Green J; Susa M
Bone; 1999 May; 24(5):437-49. PubMed ID: 10321903
[TBL] [Abstract][Full Text] [Related]
40. HOXA10 expression induced by Abl kinase inhibitors enhanced apoptosis through PI3K pathway in CML cells.
Sugimoto Y; Nakamura S; Okinaka K; Hirano I; Ono T; Shigeno K; Shinjo K; Ohnishi K
Leuk Res; 2008 Jun; 32(6):962-71. PubMed ID: 18190961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]